Group One Trading, L.P. Beam Therapeutics Inc. Transaction History

Group One Trading, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$23.46 - $45.07 $57,547 - $110,556	2,453 New	2,453 $81,000
Q3 2023 Nov 09, 2023	BUY	$23.01 - $32.46 $185,046 - $261,043	8,042 Added 433.06%	9,899 $238,000
Q2 2023 Aug 09, 2023	SELL	$29.32 - $35.99 $541,716 - $664,951	-18,476 Reduced 90.87%	1,857 $59,000
Q1 2023 May 12, 2023	BUY	$30.15 - $48.79 $69,736 - $112,851	2,313 Added 12.84%	20,333 $622,000
Q4 2022 Feb 09, 2023	BUY	$36.73 - $51.6 $661,874 - $929,832	18,020 New	18,020 $704,000
Q2 2022 Aug 11, 2022	SELL	$29.86 - $62.36 $2.77 Million - $5.78 Million	-92,760 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$53.73 - $82.16 $4.98 Million - $7.62 Million	92,760 New	92,760 $5.32 Million
Q4 2021 Feb 11, 2022	SELL	$68.02 - $99.06 $178,484 - $259,933	-2,624 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $221,386 - $350,566	2,624 New	2,624 $228,000
Q1 2021 May 12, 2021	SELL	$71.28 - $120.75 $284,977 - $482,758	-3,998 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$22.24 - $95.63 $88,915 - $382,328	3,998 New	3,998 $326,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.